Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review

Systematic Reviews

Ahmed Aljaberi¹  Dennis L. Sun²  Wen-Cheng Li³  Hai-Hua Chuang⁴  Tuan Le Mau⁵  Ludwig Christian Hinske⁶  Benjamin P. Geisler⁷  Farrin A. Manian⁸  Debbie Teodorescu⁹  Chinh Bui^1,10  Adam Edward Lang^1,11  Lara Zahabi^1,12  Elad Sharon^1,13  Knakita Clayton-Johnson^1,14  Chang-Berm Kang^1,15  Elaine Tennant^1,16  Ljiljana Lukic^1,17  Haining Yu^1,18  Adam G. Dunn^1,19  Naomi Eastwood^2,20 

[1] Brigham and Women’s Hospital, Boston, MA, USA;California Polytechnic State University, San Luis Obispo, CA, USA;Chang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan;Chang Gung Memorial Hospital/Chang Gung University, Taoyuan, Taiwan;National Taipei University of Technology, Taipei, Taiwan;Geisinger Medical Center, Danville, PA, USA;Institute of High Performance Computing, Singapore, Singapore;Ludwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany;Ludwig Maximilian University, Marchionistr. 15, 81377, Munich, Germany;Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA;Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA;Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA;Massachusetts Institute for Technology, Cambridge, MA, USA;Massachusetts Institute for Technology, Cambridge, MA, USA;McDonald Army Health Center, Fort Eustis, VA, USA;McGill University, Montreal, Canada;National Cancer Institute, Bethesda, MD, USA;Portmore Hospital Complex, Portmore, Jamaica;Proof Biotechnologies, Inc., Columbia, SC, USA;Royal North Shore Hospital, Sydney, NSW, Australia;University of New South Wales, Sydney, NSW, Australia;University Hospital for Infectious Disease Zagreb “Dr. Fran Mihaljevic”, Zagreb, Croatia;University of California San Francisco Medical Center, San Francisco, CA, USA;University of Sydney, Sydney, NSW, Australia;Wirral University Teaching Hospital NHS Foundation Trust, Wirral, UK;

关键词: COVID-19;    SARS-CoV2;    Severe acute respiratory syndrome;    SARS;    Middle East respiratory syndrome Coronavirus;    MERS-CoV;    Repurposed;    Repurposing;   

DOI  :  10.1186/s13643-021-01693-7

来源: Springer

【 摘 要 】

BackgroundCoronavirus disease 2019 (COVID-19) has no confirmed specific treatments. However, there might be in vitro and early clinical data as well as evidence from severe acute respiratory syndrome and Middle Eastern respiratory syndrome that could inform clinicians and researchers. This systematic review aims to create priorities for future research of drugs repurposed for COVID-19.MethodsThis systematic review will include in vitro, animal, and clinical studies evaluating the efficacy of a list of 34 specific compounds and 4 groups of drugs identified in a previous scoping review. Studies will be identified both from traditional literature databases and pre-print servers. Outcomes assessed will include time to clinical improvement, time to viral clearance, mortality, length of hospital stay, and proportions transferred to the intensive care unit and intubated, respectively. We will use the GRADE methodology to assess the quality of the evidence.DiscussionThe challenge posed by COVID-19 requires not just a rapid review of drugs that can be repurposed but also a sustained effort to integrate new evidence into a living systematic review.Trial registrationPROSPERO 2020 CRD42020175648

【 授权许可】

CC BY